{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:23:59Z","timestamp":1770960239648,"version":"3.50.1"},"reference-count":8,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,12,12]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>This case describes a woman in her mid-40s with recurrent colorectal cancer who developed severe dermatologic toxicity during panitumumab-based therapy. Three months after treatment initiation, she developed a diffuse acneiform eruption, pronounced xerosis and painful periungual inflammation with exuberant granulation tissue consistent with epidermal growth factor receptor (EGFR)-inhibitor\u2013induced paronychia. Multidisciplinary, guideline-concordant supportive care (including prompt topical measures and short-course systemic therapy) achieved symptom control and allowed continuation of anticancer treatment. This report underscores the importance of early recognition and structured management of EGFR-inhibitor toxicities to prevent treatment disruption and preserve quality of life.<\/jats:p>","DOI":"10.1136\/bcr-2025-266250","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:50:13Z","timestamp":1767678613000},"page":"e266250","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Relationship between recurrent colorectal cancer and EGFR inhibitor-induced dermatological side effects: a focus on paronychia"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4475-3501","authenticated-orcid":false,"given":"Omer","family":"Esmez","sequence":"first","affiliation":[{"name":"Ortopedia and travmatology, Elaz\u0131\u011f Fethi Sekin City Hospital, El\u00e2z\u0131\u011f, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merve","family":"Y\u0131ld\u0131z Esmez","sequence":"additional","affiliation":[{"name":"Firat Universitesi, Elaz\u0131\u011f, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guln\u0130hal","family":"Deniz","sequence":"additional","affiliation":[{"name":"Erzurum Technical University, Erzurum, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"2026010521500718000_19.1.e266250.1","doi-asserted-by":"publisher","DOI":"10.2165\/11205090-000000000-00000"},{"key":"2026010521500718000_19.1.e266250.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805019"},{"key":"2026010521500718000_19.1.e266250.3","first-page":"85","article-title":"Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review","volume":"17","author":"Lacouture","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"2026010521500718000_19.1.e266250.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1970"},{"key":"2026010521500718000_19.1.e266250.5","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.6004\/jnccn.2009.0074","article-title":"NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer","volume":"7","author":"Burtness","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"2026010521500718000_19.1.e266250.6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1468-3083.2009.03516.x","article-title":"Microbiological analysis of EGFR inhibitor therapy\u2013associated paronychia","volume":"24","author":"Eames","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026010521500718000_19.1.e266250.7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0051"},{"key":"2026010521500718000_19.1.e266250.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.005"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-266250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:50:13Z","timestamp":1767678613000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-266250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,5]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bcr-2025-266250"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-266250","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}